NCM
TVRD

Northstar Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Northstar Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$6K Hold
9
– – 0.01% 86
2019
Q2 		$7K Hold
9
– – 0.01% 86
2019
Q1 		$7K Buy
+9
New +$5.39K 0.01% 87

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Northstar Capital Management's TVRD Position: Q3 2019 in Review

Northstar Capital Management held its Tvardi Therapeutics (TVRD) position steady in Q3 2019 at 9 shares worth $6K. The position accounts for 0.01% of the portfolio, ranked #86.

Northstar Capital Management first reported a position in TVRD in Q1 2019 and has held it in 3 quarters since. The position peaked at $7K in Q2 2019. 144 funds tracked by Wall St. Rank hold TVRD as of Q3 2019.

  • Northstar Capital Management held 9 shares of Tvardi Therapeutics worth $6K as of Q3 2019.
  • Northstar Capital Management left its Tvardi Therapeutics share count unchanged in Q3 2019.
  • Tvardi Therapeutics made up 0.01% of Northstar Capital Management's portfolio in Q3 2019, its #86 holding.
  • Northstar Capital Management first reported a position in Tvardi Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • Northstar Capital Management's Tvardi Therapeutics position peaked at $7K in Q2 2019.
  • 144 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2019.

Based on Northstar Capital Management's 13F filing for Q3 2019, filed 7 Nov 2019.